Global Pituitary ACTH Hypersecretion Drug Market Size By Type (AT-814, ATR-101), By Application (Clinic, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Pituitary ACTH Hypersecretion Drug Market was valued at USD 415 million in 2023 and is projected to reach USD 712 million by 2031, growing at a CAGR of 6.9% during the forecast period (2023–2031). The market growth is primarily driven by rising awareness of endocrine disorders, an increasing number of patients diagnosed with Cushing’s disease and ectopic ACTH syndrome, and advancements in drug development focused on pituitary hormone regulation.

Drugs targeting adrenocorticotropic hormone (ACTH) hypersecretion are becoming increasingly critical in managing conditions associated with excess cortisol production. The surge in research and clinical trials, coupled with a rise in healthcare spending globally, is accelerating the market demand.

Drivers:

1. Rising Prevalence of Cushing’s Disease and Ectopic ACTH Syndrome: The growing incidence of ACTH-related disorders is a major driver of demand for targeted therapies. Increased diagnostic capabilities and broader clinical recognition are fueling market expansion.

2. Advancements in Drug Development: Pharmaceutical innovation, including targeted therapies like steroidogenesis inhibitors and somatostatin analogs, is improving treatment outcomes, propelling market growth.

3. Improved Awareness and Early Diagnosis: Campaigns by endocrine societies and non-profits have enhanced public and professional awareness, leading to earlier diagnosis and treatment initiation.

Restraints:

1. High Treatment Costs: Therapies for ACTH hypersecretion can be costly, particularly those involving novel targeted drugs. This limits access, especially in low-income regions.

2. Limited Drug Approvals and Availability: A restricted number of approved drugs and ongoing regulatory hurdles may slow down broader market penetration.

Opportunity:

1. Expansion in Emerging Markets: Rapid healthcare infrastructure development in Asia-Pacific and Latin America presents untapped potential for market expansion.

2. Innovation in Combination Therapies: The integration of ACTH-targeting drugs with adjunct therapies could enhance patient outcomes, offering pharmaceutical companies a path to differentiation and market growth.

3. Increased Focus on Personalized Medicine: Precision-based therapies for endocrine disorders are gaining traction, creating space for biomarker-driven drug development in the ACTH domain.

Market by System Type Insights:

Based on system type, Steroidogenesis Inhibitors led the market in 2023. These drugs, such as ketoconazole and metyrapone, remain the frontline treatment for controlling cortisol production in ACTH hypersecretion syndromes.

However, Somatostatin Analogs are expected to witness the highest growth rate, driven by their emerging application in inhibiting ACTH release directly from pituitary tumors, offering an alternative when surgery is not viable.

Market by End-Use Insights:

In terms of end use, Hospitals and Specialty Clinics accounted for the largest market share in 2023. These institutions are at the forefront of managing rare endocrine conditions, supported by dedicated endocrinology departments and access to advanced diagnostics.

Meanwhile, Research & Academic Institutes are projected to grow significantly, given the rising focus on pituitary disease research and expanding clinical trials pipeline for ACTH-modulating drugs.

Market by Regional Insights:

North America dominated the global market in 2023 due to the presence of advanced healthcare systems, robust clinical research infrastructure, and a high diagnosis rate of rare endocrine conditions. The Asia-Pacific region is anticipated to register the fastest growth rate, propelled by increasing healthcare spending, growing awareness, and rising patient pool across countries like India, China, and Japan.

Competitive Scenario:

Key players in the global pituitary ACTH hypersecretion drug market include Recordati S.p.A., Novartis AG, Ipsen, HRA Pharma, Corcept Therapeutics, Crinetics Pharmaceuticals, Strongbridge Biopharma, and Neurocrine Biosciences. These companies are focusing on expanding their drug portfolios, conducting late-stage clinical trials, and securing regulatory approvals.

Key developments include:

In 2023, Recordati expanded the global reach of Isturisa® (osilodrostat) following successful launches in Asia and Latin America.

Crinetics Pharmaceuticals initiated Phase III trials of its oral non-peptide ACTH antagonist, showcasing strong early efficacy.

Neurocrine Biosciences announced a strategic collaboration in 2024 for research into gene-targeted therapies for Cushing’s disease.

Scope of Work – Global Pituitary ACTH Hypersecretion Drug Market

Report Metric Details

Market Size (2023) USD 415 million

Projected Market Size (2031) USD 712 million

CAGR (2023–2031) 6.9%

Key Segments System Type (Steroidogenesis Inhibitors, Somatostatin Analogs), End-use (Hospitals & Clinics, Research Institutes)

Growth Drivers Rise in ACTH-related disorders, Advancements in endocrinology drugs, Early diagnosis initiatives

Opportunities Emerging markets, Personalized medicine, Combination drug strategies

Key Market Developments:

2023: Recordati received expanded approval for Isturisa® across multiple countries in Asia-Pacific.

2024: Neurocrine Biosciences initiated a novel gene therapy research program targeting pituitary tumors secreting ACTH.

2025: Corcept Therapeutics advanced its selective GR modulator pipeline for Cushing’s syndrome into Phase II trials.

FAQs:

1) What is the current market size of the Global Pituitary ACTH Hypersecretion Drug Market?

The market was valued at USD 415 million in 2023.

2) What is the major growth driver of the Global Pituitary ACTH Hypersecretion Drug Market?

The major growth driver is the rising prevalence of ACTH-related disorders such as Cushing’s disease and advancements in drug development.

3) Which is the largest region during the forecast period in the Global Pituitary ACTH Hypersecretion Drug Market?

North America remains the largest region due to advanced healthcare systems and higher disease awareness.

4) Which segment accounted for the largest market share in the Global Pituitary ACTH Hypersecretion Drug Market?

The Steroidogenesis Inhibitors segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Pituitary ACTH Hypersecretion Drug Market?

Key players include Recordati, Novartis, Ipsen, HRA Pharma, Corcept Therapeutics, Crinetics Pharmaceuticals, and Neurocrine Biosciences.